September 19, 2019
Marlene Rabinovitch–Novel Molecular Pathways in Pulmonary Hypertension

Marlene Rabinovitch–Novel Molecular Pathways in Pulmonary Hypertension

(upbeat music) – So, welcome back to ATVB 2013. It’s Thursday night, and
we’re getting ready for our council dinner tonight. But we have one more very exciting session tomorrow morning, which is our invited lecture series. And I’m happy to be here tonight with Dr. Marlene Rabinovitch
from Stanford University, who will be delivering
the ATVB key note lecture tomorrow morning at that session. And you’ve just arrived in
town, I think you’re really going to enjoy the meeting tomorrow. Is there any kind of
preview you can give us for what you’ll be talking about tomorrow? – First, Steve, thanks so
much for the invitation. It’s a great honor, and I’m really overwhelmed by the tribute, so thanks very much again. – Great to have you here. – I can give you a bit of a preview. What I’d like to do is tell
the group a little bit about the developments in our
laboratory that have led to new emerging treatments
for pulmonary hypertension, and then to show how these
treatments might have broader impact and importance in
other vascular pathologies that are much more common
than pulmonary hypertension. And also show how identification of a gene that is mutant in familial
forms of pulmonary hypertension has really provided new
insights into these pathways. And recently, it’s been described
that that same mutant gene can make atherosclerosis much more severe in an animal model. So I think there’ll be a
lot of connections between the disease that we
studied that is more rare, pulmonary hypertension, and the broader range of
vascular pathology that your audience deals with. – I think we’ve already
seen several examples of that in this meeting
so far this week, where insights gained from
studying a rare disease, a less common disease,
is really quite relevant to vascular biology and
other disease types. And one of the nice things about ATVB is it brings together people
from these different fields. It shows how the molecular
insights can be transferred. I also think the focus on
the pulmonary vasculature is interesting because not only is it important for
pulmonary hypertension, but the pulmonary vascular
bed is very interesting developmentally, and has been
understudied over the years. – Absolutely, and the
disease that we studied, pulmonary hypertension, is
devastating as you know. It’s diagnosed usually very late, because the vascular pathology
is really quite advanced in many patients by the time
they become symptomatic, or at least come to the attention
of physicians that think about the disease. So I think a lot of groups, such as the Pulmonary Hypertension Association, have increased awareness of this disease. But, it also is one in which we’re really very much trying to make new inroads, because of the severity, and because it affects young
people, primarily women in the prime of their life. – Yeah, as a hematologist
that’s interested in thrombosis, I sometimes see patients that
have a thromboembolic form of pulmonary hypertension,
– Correct. – and also get into discussions
sometimes about the role of clotting factors and
anticoagulants in the management of the disease more broadly. – And that’s still very
controversial, as you know, because I think another
new frontier is really better understanding
thrombotic and thromboembolic phenomena in the pathobiology
of pulmonary hypertension. That for sure has been under-studied. There are patients with
thromboembolic disease that do very well after
thromboendarterectomy, but as you know, there are others that appear to not develop a reversal of
the pulmonary hypertension. In fact, the disease progresses
just as it does in the idiopathic form. – Yes. Well, this will be a fantastic
presentation, I’m sure. And hopefully it’ll see
ideas for some of the young investigators here at the meeting to take on some of these challenges. So, again, thanks for coming,
and we look forward to your talk tomorrow. – I look forward to it as well. Thanks very much, Steve, again. (upbeat music)

Leave a Reply

Your email address will not be published. Required fields are marked *